Infusional chemoradiation for rectal and anal cancers

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Combined-modality therapy (CMT) with irradiation and chemotherapy is standard for anal and rectal cancers.
• Bolus 5-fluorouracil with irradiation improves survival but increases toxicity.
• Fractionation in radiation oncology suggests protracted infusion may reduce chemotherapy toxicity.

Purpose of the Study:

• To evaluate the efficacy and toxicity of protracted venous infusion (PVI) chemotherapy concurrent with irradiation for anal and rectal cancers.
• To explore the benefits of PVI in managing micrometastatic disease and enhancing radiation sensitization.
• To discuss the role of PVI chemoradiation in preoperative rectal cancer and nonoperative anal cancer management.

Main Methods:

• Review of clinical trial data on combined-modality therapy for anal and rectal cancers.
• Comparison of outcomes between bolus chemotherapy and protracted venous infusion chemotherapy regimens.
• Analysis of toxicity profiles associated with different chemotherapy administration schedules.

Main Results:

• Protracted venous infusion chemotherapy concurrent with irradiation demonstrates efficacy and a wide therapeutic index.
• PVI reduces normal tissue toxicity compared to bolus 5-fluorouracil administration.
• PVI allows for concurrent systemic treatment of micrometastatic disease and radiation sensitization.

Conclusions:

• Protracted venous infusion chemoradiation is an effective and tolerable treatment for anal and rectal cancers.
• PVI is valuable in preoperative rectal cancer and nonoperative anal cancer management.
• Advancements in radiosensitizers and radiotherapy techniques hold promise for improved CMT outcomes.